Futhan

Torii Pharmaceutical is a prominent Japanese pharmaceutical company specializing in the development and commercialization of treatments for renal diseases, hemodialysis, skin diseases, and allergies. The company is widely recognized for its flagship product Futhan (nafamostat mesylate), a potent serine protease inhibitor used primarily for acute pancreatitis and disseminated intravascular coagulation. As a subsidiary of Japan Tobacco (JT), Torii maintains a strong focus on the Japanese domestic market while leveraging its parent company's global resources. Its portfolio includes a diverse range of therapies, from small molecule inhibitors to allergen immunotherapies, addressing significant unmet needs in chronic and acute care settings.